Del Toro Natalia Pelet, Wu Jashin J, Han George
Drs. Pelet del Toro and Han are from the Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York. Dr. Wu is from the Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Florida.
Cutis. 2023 Feb;111(2):101-104. doi: 10.12788/cutis.0701.
The landscape of psoriasis treatments has undergone rapid change within the last decade and the dizzying speed of drug development has not slowed, with 4 notable entries into the psoriasis treatment armamentarium within the last year: tapinarof, roflumilast, deucravacitinib, and spesolimab. Several others are in late-stage development, and these therapies represent new mechanisms, pathways, and delivery systems, meaningfully broadening the spectrum of treatment choices for our patients. However, it can be quite difficult to keep track of all the medication options. This review aims to present the mechanisms and data on both newly available therapeutics for psoriasis and products in the pipeline that may have a notable impact on our treatment paradigm for psoriasis in the near future.
在过去十年里，银屑病的治疗格局发生了迅速变化，药物研发的惊人速度并未放缓，去年有4种药物显著加入了银屑病治疗药物库：他扎罗芬、罗氟司特、德卡伐替尼和司泊利单抗。还有其他几种药物正处于后期研发阶段，这些疗法代表了新的作用机制、途径和给药系统，切实拓宽了我们为患者提供的治疗选择范围。然而，要跟踪所有的药物选择可能相当困难。本综述旨在介绍银屑病新可用疗法以及即将推出的产品的作用机制和数据，这些产品可能在不久的将来对我们的银屑病治疗模式产生显著影响。
